These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 23028623

  • 1. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
    Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H.
    PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
    [Abstract] [Full Text] [Related]

  • 2. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
    Sunpath H, Winternheimer P, Cohen S, Tennant I, Chelin N, Gandhi RT, Murphy RA.
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):689-93. PubMed ID: 24903940
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis.
    Boulanger C, Rolla V, Al-Shaer MH, Peloquin C.
    Int J Antimicrob Agents; 2020 Feb; 55(2):105840. PubMed ID: 31704214
    [Abstract] [Full Text] [Related]

  • 6. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA.
    Clin Infect Dis; 2021 Aug 16; 73(4):706-715. PubMed ID: 34398956
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
    Mulindwa F, Castelnuovo B, Kirenga B, Kalibbala D, Haguma P, Muddu M, Semitala FC.
    BMC Infect Dis; 2021 Aug 16; 21(1):822. PubMed ID: 34399706
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US.
    Eur J Clin Pharmacol; 2010 Oct 16; 66(10):1017-23. PubMed ID: 20552180
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J, OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team.
    PLoS Med; 2012 Oct 16; 9(6):e1001236. PubMed ID: 22719231
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.
    Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T.
    PLoS One; 2011 Feb 23; 6(2):e17273. PubMed ID: 21383838
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN, Capparelli EV, McIlleron H, Gerhart JG, Dumond JB, Kashuba ADM, Denti P, Gonzalez D.
    Pharmacotherapy; 2023 Jul 23; 43(7):638-649. PubMed ID: 35607886
    [Abstract] [Full Text] [Related]

  • 17. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V, MONOD Study Group.
    BMC Med; 2017 Apr 24; 15(1):85. PubMed ID: 28434406
    [Abstract] [Full Text] [Related]

  • 18. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Svensson EM, Dooley KE, Karlsson MO.
    Antimicrob Agents Chemother; 2014 Nov 24; 58(11):6406-12. PubMed ID: 25114140
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.